A new innovative medical device, known as EchoGo Pro, has been developed by the UK-based health tech firm, Ultromics, to use artificial intelligence technology to predict coronary artery disease in patients. According to the World Health Organisation, approximately 17 million deaths per year are caused by cardiovascular diseases, making it the number one cause of death around the world. EchoGo Pro is able to detect heart disease by using AI-operated ultrasound analysis to scan images of the heart and identify the presence of a cardiovascular condition. Diagnosing heart disease is an extremely complicated process, due to complex symptoms, comorbidities and circumstances that make it difficult for health professionals to identify the disease visually. In fact, approximately 1 in 5 patients are misdiagnosed with heart disease due to the difficulty in diagnosing it.

As it matures, machine learning has been applied to more and bigger challenges. One of the latest is women's health tech, a space where research has traditionally lagged, and that few companies have addressed, until now. In 2015, women's health tech startups raised only $82 million in funding from investment firms. Since then, that number has risen to $1.1 billion. AI health care company Presagen is one of the companies stepping up in this essential health space, with scalable machine learning that can be used by clinics and patients anywhere in the world.

LOS ANGELES, June 26, 2019 /PRNewswire-PRWeb/ -- An Ovation Fertility abstract about the use of artificial intelligence in IVF, presented at the 35th European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting on June 24, 2019, was pre-selected for consideration for two prestigious awards at the event: The Basic Science Award for Oral Presentation, awarded to the presenting author of the best oral presentation on a basic science topic, and the Fertility Society of Australia Exchange Award, which provides an educational travel grant for the presenting author to present the data of his/her oral presentation at the annual meeting of the Fertility Society of Australia (FSA). Only five presentations at ESHRE 2019 were selected to receive awards and be rewarded with a prize of EURO 2,000, and one additional presentation was selected for the FSA Exchange Award. Special award committees, composed of senior scientists and clinicians, made the selections for each award. Ovation's oral presentation about the use of artificial intelligence in IVF, "Artificial intelligence (AI) technology can predict human embryo viability across multiple laboratories with varying demographics with high accuracy and reproducibility," detailed a study that sought to find out if artificial intelligence (AI) and computer vision can improve embryo viability prediction using static 2D images of Day 5 embryos from multiple laboratories. In most IVF labs, embryologists select which embryos to transfer based on morphological assessment, using high-powered microscopes to examine each embryo and assign it a subjective "grade."

ARTIFICIAL Intelligence technology is being used by an Aussie startup to help select the healthiest embryos for use in IVF treatments. Life Whisperer is based in South Australia and uses a combination of computer vision, human analysis and machine learning techniques to identify healthy embryos for implantation. The non-invasive embryo selection technique applies key algorithms that recognise important information, including morphological features, to grade embryo quality. The company is looking to identify a commercial partner to conduct the next validation phase of its technology. Co-founder and Managing Director Dr Michelle Perugini said machine learning meant the system could efficiently study "tens of thousands" of retrospective cases and build a portfolio of information.